Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
/
AstraZeneca
AZN
AstraZeneca
US And Europe Drug Reforms Will Erode Pricing Power
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
28 Jul 25
Updated
28 Jul 25
1
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
UK£109.16
1.3% overvalued
intrinsic discount
28 Jul
UK£110.54
Loading
1Y
-12.9%
7D
-3.9%
Author's Valuation
UK£109.2
1.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
UK£109.2
1.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-1b
61b
2014
2017
2020
2023
2025
2026
2028
Revenue US$60.9b
Earnings US$11.7b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.78%
Pharma revenue growth rate
1.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.82%
Calculation
US$11.68b
Earnings '28
x
23.57x
PE Ratio '28
=
US$275.36b
Market Cap '28
US$275.36b
Market Cap '28
/
1.55b
No. shares '28
=
US$177.65
Share Price '28
US$177.65
Share Price '28
Discounted to 2025 @ 6.64% p.a.
=
US$146.47
Fair Value '25
US$146.47
Fair Value '25
Converted to GBP @ 0.7452 USD/GBP Exchange Rate
=
UK£109.15
Fair Value '25